PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.06%
Revenue growth under 50% of VET's 13.22%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
8.02%
Gross profit growth at 50-75% of VET's 11.68%. Martin Whitman would question if cost structure or brand is lagging.
32.10%
EBIT growth above 1.5x VET's 12.47%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
32.10%
Operating income growth above 1.5x VET's 12.47%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
-37.05%
Negative net income growth while VET stands at 19.13%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-35.36%
Negative EPS growth while VET is at 19.05%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-35.27%
Negative diluted EPS growth while VET is at 18.03%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-2.40%
Share reduction while VET is at 0.40%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.46%
Reduced diluted shares while VET is at 0.61%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.04%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-28.82%
Negative OCF growth while VET is at 27.90%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-59.97%
Negative FCF growth while VET is at 32.86%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
55.68%
10Y revenue/share CAGR under 50% of VET's 2268.99%. Michael Burry would suspect a lasting competitive disadvantage.
55.68%
5Y revenue/share CAGR under 50% of VET's 140.44%. Michael Burry would suspect a significant competitive gap or product weakness.
168.76%
3Y revenue/share CAGR above 1.5x VET's 107.06%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
150.35%
Positive 3Y OCF/share CAGR while VET is negative. John Neff might see a big short-term edge in operational efficiency.
393.30%
Below 50% of VET's 3644.56%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
393.30%
5Y net income/share CAGR above 1.5x VET's 240.99%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
640.48%
3Y net income/share CAGR above 1.5x VET's 227.99%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
364.68%
Below 50% of VET's 749.00%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
364.68%
5Y equity/share CAGR above 1.5x VET's 68.19%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
164.04%
3Y equity/share CAGR above 1.5x VET's 63.99%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
457.61%
3Y dividend/share CAGR above 1.5x VET's 11.08%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-3.37%
Firm’s AR is declining while VET shows 52.24%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
39.43%
Inventory growth well above VET's 7.65%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
2.32%
Asset growth well under 50% of VET's 14.60%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
4.82%
Similar to VET's 4.86%. Walter Schloss finds parallel capital usage or profit distribution strategies.
6.76%
Debt growth far above VET's 7.45%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-28.01%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.